X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Expansion of Intellectual Property portfolio for its supportive care drugs under development generated cerium oxide nanoparticle technology an IV formulation for protection of normal internal tissue from radiation damage, topical formulation for protection of cancer patient.
Lead Product(s): Cerium Oxide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue.
Lead Product(s): Cerium Oxide,Tolfenamic Acid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy.
Lead Product(s): Cerium Oxide,Radiation therapy,Chemotherapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
